Novocure (NASDAQ:NVCR) has met the primary endpoint of overall survival in a late-stage trial evaluating the use of its Tumor ...

Novocure shares jumped 26% in premarket trading following trial results of a therapy for pancreatic cancer. Shares were trading around $25.22. The stock is up 34% on the year.

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer ...

Initial results with gemcitabine (Gem) and mitomycin C (MMC) appeared promising but shortages in MMC led to the need to substitute docetaxel (Doce) for MMC to create Gem/Doce. Both were developed ...

Pancreatic cancer is the fourth leading cause of cancer death in the US, with over 35,000 deaths reported in 2009. 1 In 1997, gemcitabine became the standard of care for advanced disease and since ...

For patients with advanced or metastatic pancreatic cancer, gemcitabine is the standard therapy; however, although gemcitabine therapy increases overall survival, response rates are low.

Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using gemcitabine. Gemcitabine may harm an unborn baby. Your doctor should order a pregnancy ...

Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or ...

High-dose intravenous vitamin C doubles survival in metastatic pancreatic cancer, extending life without added toxicity or ...

Nasopharyngeal carcinoma (NPC) is a rare, aggressive form of head and neck cancer that originates in the nasopharynx, the ...

The drug is the only immuno-oncology drug approved by various regulatory authorities around the world for the treatment of ...